Brimonidine Tartrate / Brinzolamide Combination Ophthalmic Suspension (Ailamide® / アイラミド配合懸濁性点眼液)

JPY ¥11,800

Japanese alpha-2 agonist/carbonic anhydrase inhibitor combination ophthalmic suspension (Brimonidine Tartrate 1mg/mL + Brinzolamide 10mg/mL). Ophthalmic instillation for glaucoma and ocular hypertension. 5mL x 5 bottles. Mfd. by Senju Pharmaceutical Co., Ltd., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥10,856
10 - 19 12% JPY ¥10,384
20 + 18% JPY ¥9,676
SKU: AIL-01-OPH Category:

Description

Product Overview / 商品概要

Ailamide Combination Ophthalmic Suspension (アイラミド配合懸濁性点眼液)
Generic: Brimonidine Tartrate / Brinzolamide Combination Ophthalmic Suspension / ブリモニジン酒石酸塩・ブリンゾラミド配合懸濁性点眼液
Therapeutic Category: Alpha-2 Agonist / Carbonic Anhydrase Inhibitor Combination Agent for Glaucoma and Ocular Hypertension / α2作動薬/炭酸脱水酵素阻害薬配合剤 緑内障・高眼圧症治療剤
Manufactured by: Senju Pharmaceutical Co., Ltd. / 千寿製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Brimonidine Tartrate 1mg and Brinzolamide 10mg per 1mL / 1mL中 ブリモニジン酒石酸塩 1mg、ブリンゾラミド 10mg
Additives: Tyloxapol, Concentrated glycerin, Boric acid, Carboxy vinyl polymer, Edetate sodium hydrate, Benzalkonium chloride, Tonicity agent, pH adjusting agent / チロキサポール、濃グリセリン、ホウ酸、カルボキシビニルポリマー、エデト酸ナトリウム水和物、ベンザルコニウム塩化物、等張化剤、pH調節剤
Appearance: Sterile aqueous ophthalmic suspension, white to slightly yellowish-white upon shaking. pH: 6.3–6.8, osmolarity ratio to saline: 0.9–1.2
外観: 振り混ぜるとき、白色~微黄白色の無菌水性懸濁点眼剤。pH: 6.3~6.8、生理食塩液に対する比: 0.9~1.2

Indications / 効能効果

EN: Glaucoma and ocular hypertension in cases where other glaucoma medications are inadequate
JA: 次の疾患で、他の緑内障治療薬が効果不十分な場合:緑内障、高眼圧症

Dosage and Administration / 用法用量

EN: Instill 1 drop twice daily.
JA: 1回1滴、1日2回点眼する。

Contraindications / 禁忌

EN: 1. Patients with a history of hypersensitivity to any component of this product. 2. Low birth weight infants, neonates, infants, or children under 2 years of age. 3. Patients with severe renal impairment.
JA: 1. 本剤の成分に対し過敏症の既往歴のある患者。2. 低出生体重児、新生児、乳児又は2歳未満の幼児。3. 重篤な腎障害のある患者。

Regulatory Information / 規制情報

Approval No.: 30200AMX00436
Sales Started: June 2020 / 2020年6月
Classification Code: 871319
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 5mL x 5 / 5mL×5
Other Available Packages (by special order): Plastic ophthalmic container 5mL x 5, 5mL x 10

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Brimonidine Tartrate / Brinzolamide Combination Ophthalmic Suspension (Ailamide® / アイラミド配合懸濁性点眼液)”

メールアドレスが公開されることはありません。 が付いている欄は必須項目です

Export from Japan — Brimonidine Tartrate

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.